Close
Portfolio

Starfish Ventures invests in companies across a diverse range of industries and technologies including life sciences, clean technology, and information technology.

Life Sciences

Team Members
    Portfolio Items
    • Armaron Bio

      Armaron Bio is a life sciences start-up company based in Melbourne. Armaron Bio is developing proprietary lead cardioprotectant and neuroprotectant small molecules to reduce tissue damage following a heart attack or stroke. Its lead compound is presently in Phase I clinical development and will enter a Proof of Concept Phase II trial in 2015.

    • dorsaVi

      dorsaVi Pty Ltd (previously Pro-Active Medical Pty Ltd) is a biotechnology company focused on developing innovative motion analysis device technologies. 

      dorsaVi has three distinct products: ViMove for the clinical market, ViSafe for the work safety market and ViPerform for the sport market.

      dorsaVi listed on the ASX in December 2013 - DVL.ASX .

    • ImpediMed

      ImpediMed is a medical device company that designs, develops and markets proprietary bioimpedance analysis systems for use in non-invasive screening and monitoring of human disorders and diseases. ImpediMed markets products in three core areas, body composition for medical applications, hydration status monitoring and the detection and monitoring of lymphoedema and oedema.

      Impedimed was listed on the Australian Stock Exchange in October 2007 (ASX:IPD). 

    • Intersection Medical

      Intersection Medical develops, markets, and continuously improves innovative non-invasive medical technology to assist physicians and their patients in proactively managing heart failure and improving both clinical outcomes and reducing cost of care.

      Our devices provide physicians with improved information with which to manage heart failure, and provide heart failure patients with increased personal control over their disease states through regular monitoring of fluid status in their home setting and self-initiation of timely and appropriate medical management interventions.

       

       

       

    • Mimetica

      Mimetica is a Brisbane-based biotechnology company which has developed a proprietary class of small molecule scaffolds that mimic reverse-turn motifs of peptides. These scaffolds have been used to create novel small molecule mimics of several important peptides and proteins known to be involved in the pathogenesis of disease. Mimetica is currently focusing its initial drug development activities on dermatological applications.

    • MuriGen Therapeutics

      MuriGen Therapeutics is a drug discovery and development company established by the Walter and Eliza Hall Institute of Medical Research (WEHI).

      MuriGen is building a portfolio of novel drugs for unmet medical needs across a number of therapeutic areas including cancer, arthritis, thrombocytopenia, inflammation, epilepsy and thalassemia.

    • NephroDynamics

      Nephrodynamics focused on drugs treating kidney failure during and after septic shock. 

       

    • Protagonist

      Protagonist is focused on the discovery of drug candidates for targets previously resistant to small molecule discovery (protein-protein interactions) and on designing and constructing arrays of molecules that sample biologically-relevant regions of chemical diversity.

    News Articles